M. Kabeya

发表

Physiology and pathophysiology of proteinase-activated receptors (PARs): PAR-2 as a potential therapeutic target.

T. Kanke, A. Kawabata, T. Takizawa, 2005, Journal of pharmacological sciences.

Binding of a highly potent protease‐activated receptor‐2 (PAR2) activating peptide, [3H]2‐furoyl‐LIGRL‐NH2, to human PAR2

R. Plevin, T. Kanke, H. Ishiwata, 2005, British journal of pharmacology.

Novel antagonists for proteinase‐activated receptor 2: inhibition of cellular and vascular responses in vitro and in vivo

S. Kondo, R. Plevin, T. Kanke, 2009, British journal of pharmacology.

THEMED ISSUE: GPCR RESEARCH PAPER Novel antagonists for proteinase-activated receptor 2: inhibition of cellular and vascular responses in vitro and in vivo

S. Kondo, R. Plevin, T. Kanke, 2009 .

An alternative efficient synthesis of the C20–C25 building unit for calyculin A

Y. Hamada, T. Shioiri, M. Kabeya, 1997 .

Synthesis of γ-lactone derivatives as a key intermediate for the spiroketal fragment in calyculin A

Y. Hamada, T. Shioiri, M. Kabeya, 1997 .

An efficient synthesis of C20–C25 building blocks for calyculin A

Y. Hamada, F. Yokokawa, K. Hatano, 1996 .

Synthesis of oxidative metabolites of K-115, a novel Rho-kinase inhibitor

K. Kawamura, M. Kabeya, K. Shibuya, 2021, Tetrahedron Letters.

Potent and Metabolically Stable Agonists for Protease-Activated Receptor-2: Evaluation of Activity in Multiple Assay Systems in Vitro and in Vivo

Toru Kanke, R. Plevin, T. Kanke, 2004, Journal of Pharmacology and Experimental Therapeutics.